Issue link: https://beckershealthcare.uberflip.com/i/1293265
20 DEVICES & IMPLANTS Medtronic, DePuy Synthes in spine: 5 key comparisons By Laura Dyrda M edtronic and Johnson & Johnson's DePuy Synthes lead the spine market and continue to make interesting moves to expand their presence in the field. Here are five key points of comparison: 1. Financials Medtronic: Restorative erapies Group (in- cluding spine) has $8.2 billion in revenue DePuy Synthes: $10 billion in annual sales 2. Quarterly spine revenue Medtronic reported spine revenue dropped 31 percent year over year to $480 million in the fourth quarter of the 2020 fiscal year. BMP sales were down more than 30 percent. Johnson & Johnson Orthopaedics reported $2 billion in worldwide revenue for the first quarter of 2020, a 7.5 percent year-over-year drop. Quarterly spine, sports and other sales were down 10.7 percent to $703 million. 3. Market share Medtronic: 29 percent DePuy Synthes: 16 percent *According to e Spine Market Group. 4. Leadership Brett Wall is the executive vice president and president of Medtronic's Restorative era- pies Group, which includes brain therapies, pain therapies, specialty therapies and spine. He previously served as senior vice president of the group's brain therapies division and as president of Covidien's neurovascular and international business before Medtronic ac- quired the company. Ashley McEvoy is the executive vice presi- dent and worldwide chairman of medical devices at Johnson & Johnson. She leads the company's surgery, orthopedics, interven- tional solutions and eye health businesses. Ms. McEvoy has previous experience in leadership roles with Johnson & Johnson, and co-led the integration of Pfizer Con- sumer Healthcare into NcNeil, which is the company's largest integration. 5. Big moves Medtronic acquired Titan Spine in 2019 for an undisclosed amount. e company con- tributed $15 million to Medtronic's fourth quarter revenue. Medtronic acquired the Mazor robotic technology for spine surgery in December 2018 and has since worked with the company to develop the Mazor X Stealth Edition. On Sept. 25, Johnson & Johnson Medical Device Companies' DePuy Synthes launched the Conduit Interbody Platform with EIT cellular titanium technology, which includes 3D-printed titanium implants for spinal fu- sion. n Where Johnson & Johnson stands with robotics: 3 updates By Angie Stewart J ohnson & Johnson provided updates on its robotics offerings during a second-quarter earnings call transcribed by Seeking Alpha. Three takeaways: 1. Johnson & Johnson won't pursue a 510(k) pathway for its general surgery robotic platform in the U.S. due to COVID-19. Instead, it will begin first-in-human clinical studies of the robotic platform in the sec- ond half of 2022. Johnson & Johnson's general surgery offering will incorporate features from the Verb and Auris robotic platforms. "We continue to be very excited about the overall program and that our continued investment here will offer a differentiated and compet- itive product to the market with better outcomes for patients," said Johnson & Johnson Executive Vice President and CFO Joseph Wolk. 2. Johnson & Johnson is progressing toward regulatory submission for an orthopedic robotic solution that is part of the Velys digital sur- gery platform and came out of the 2018 Orthotaxy acquisition. It will initially seek clearance for use in knee surgery. 3. Johnson & Johnson sees "tremendous growth opportunity" in the digital space, where market penetration is under 5 percent, said CEO Alex Gorsky. He added, "We continue to be impressed by the technology advancements we're seeing with both the Verb and Ver- ily and the Auris combination." n Spine technology company raises $2.5M, shakes up leadership By Eric Oliver S pine-facing medical technology company Carlsmed closed a $2.5 million fundraising round and concurrently made a pair of leadership appointments. What you should know: 1. The fundraising round was led by Cove Fund II. Carlsmed will use the funds to commercialize its "data-driven surgery mission." 2. In addition to closing the round, Carlsmed appointed Andrew Arrow, MD, as chief financial officer and Shariq Hussain as chief information officer. 3. Dr. Arrow is a MedTech executive with more than 20 years of C-suite and financial leadership roles. 4. Mr. Hussain previously served as CEO and chief technology officer of IntelliGuard. n